Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [922]

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1...

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

ASCO GU 2022: Latest in mHSPC

Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith

ASCO GU 2022: Latest in mHSPC ( Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith )

ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE

Dr Neal Shore and Prof Kim Chi

ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE ( Dr Neal Shore and Prof Kim Chi )

An AI-derived digital pathology-based biomarker to predict the benefit of ADT...

Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA

An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validation in NRG/RTOG 9408 ( Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA )

SG in combination with pembro in patients with mUC who progressed after...

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion

Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA

NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion ( Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA )

Latest developments in mHSPC

Prof Kurt Miller and Prof Laura-Maria Krabbe

Latest developments in mHSPC ( Prof Kurt Miller and Prof Laura-Maria Krabbe )

Evaluating a polygenic hazard score to predict risk of developing metastatic or...

Dr Meghana Pagadala - University of California San Diego, San Diego, USA

Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer ( Dr Meghana Pagadala - University of California San Diego, San Diego, USA )

ASCO GU 2022: The latest in CRPC, including PARP combo data

Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel...

ASCO GU 2022: The latest in CRPC, including PARP combo data ( Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Merseburger )

Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma...

Dr Hielke Martijn de Vries - Netherlands Cancer Institute, Amsterdam, The...

Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis ( Dr Hielke Martijn de Vries - Netherlands Cancer Institute, Amsterdam, The Netherlands )

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in...

Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona...

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC ( Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer